Level Biotechnology (3118) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Level Biotechnology (3118) has a cash flow conversion efficiency ratio of 0.021x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$11.81 Million ≈ $372.24K USD) by net assets (NT$562.82 Million ≈ $17.73 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Level Biotechnology defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Level Biotechnology - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Level Biotechnology's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Level Biotechnology Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Level Biotechnology ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Auking Mining Ltd
AU:AKN
|
-0.199x |
|
TeraGo Inc.
TO:TGO
|
-0.032x |
|
Reino Capital SA
WAR:RNC
|
0.064x |
|
Nordic Iron Ore
ST:NIO
|
0.002x |
|
Hankukpackage Co. Ltd
KQ:037230
|
0.048x |
|
Poulaillon SA
PA:ALPOU
|
0.198x |
|
Fridenson
TA:FRDN
|
-0.054x |
|
Australian Mines Ltd
AU:AUZ
|
-0.017x |
Annual Cash Flow Conversion Efficiency for Level Biotechnology (2017–2024)
The table below shows the annual cash flow conversion efficiency of Level Biotechnology from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Level Biotechnology.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$559.91 Million ≈ $17.64 Million |
NT$64.10 Million ≈ $2.02 Million |
0.114x | -10.41% |
| 2023-12-31 | NT$549.47 Million ≈ $17.31 Million |
NT$70.21 Million ≈ $2.21 Million |
0.128x | +6.51% |
| 2022-12-31 | NT$542.40 Million ≈ $17.09 Million |
NT$65.07 Million ≈ $2.05 Million |
0.120x | -58.09% |
| 2021-12-31 | NT$544.84 Million ≈ $17.17 Million |
NT$155.95 Million ≈ $4.91 Million |
0.286x | +82.08% |
| 2020-12-31 | NT$529.43 Million ≈ $16.68 Million |
NT$83.23 Million ≈ $2.62 Million |
0.157x | -25.92% |
| 2019-12-31 | NT$513.75 Million ≈ $16.19 Million |
NT$109.02 Million ≈ $3.43 Million |
0.212x | +295.34% |
| 2018-12-31 | NT$498.78 Million ≈ $15.71 Million |
NT$26.77 Million ≈ $843.50K |
0.054x | -60.68% |
| 2017-12-31 | NT$522.28 Million ≈ $16.45 Million |
NT$71.29 Million ≈ $2.25 Million |
0.136x | -- |
About Level Biotechnology
Level Biotechnology Inc. engages in marketing and distributing cell culture, immunology, and molecular biology products in Taiwan. It markets and distributes biomedical precision equipment. The company also provides services in the areas of mammalian and genetic toxicology, pharmacology, biocompatibility, and model animal production. In addition, it offers preclinical research services to the bio… Read more